Effects of transdermal estradiol gel and oral tibolone on health‐related quality of life after surgical menopause

Bhattacharya, Saurav; Jha, Ayan

doi:10.1016/j.ijgo.2010.04.023

Cited by 9 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1), resulting in 143 publications. Of these publications, we reviewed eight comparative studies 10–17 and four single-group studies 18–21 for vaginal DHEA, 13 comparative studies 22–34 and eight single-group studies 35–42 for oral ospemifene, 11 comparative studies 43–53 and 41 single-group studies 54–94 for microablative fractional carbon dioxide (CO 2 ) laser, two comparative studies 95,96 and three single-group studies 97–99 for Erbium:YAG laser, seven comparative studies 100-106 and one single-group study 107 for the polycarbophil-based vaginal moisturizer, six comparative studies 108–113 and one single-group study 114 for testosterone, 25 comparative studies 115–138 for oral tibolone, and seven comparative studies 139–145 and five single-group studies 146–150 for vaginal hyaluronic acid. A list of reviewed publications can be found in Appendix 2 (available online at http://links.lww.com/AOG/D289), and summarized findings can be found in Tables 1 and 2.…”

Section: Resultsmentioning

confidence: 99%

“…There were 25 comparative studies that investigated tibolone. 115-138 Seven compared tibolone with placebo or no medication, 118,125–127,132,135,137 16 with oral or transdermal estrogen, 115,116,119–124,128,129,131,133,134,136,138 one with soy isoflavone, 117 and one with raloxifene. 130 The measured outcomes included VMIs (n=1,147, moderate quality of evidence), vaginal dryness (n=849, low quality of evidence), dyspareunia (n=866, low quality of evidence), and FSFI total score (n=421, moderate quality of evidence).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause

Evans

Hobson

Aschkenazi

et al. 2023

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

OBJECTIVE: To systematically review the literature and provide clinical practice guidelines regarding various nonestrogen therapies for treatment of genitourinary syndrome of menopause (GSM). DATA SOURCES: MEDLINE, EMBASE, ClinicalTrials.gov, and Cochrane databases were searched from inception to July 2021. We included comparative and noncomparative studies. Interventions and comparators were limited to seven products that are commercially available and currently in use (vaginal dehydroepiandrosterone [DHEA], ospemifene, laser or energy-based therapies, polycarbophil-based vaginal moisturizer, Tibolone, vaginal hyaluronic acid, testosterone). Topical estrogen, placebo, other nonestrogen products, as well as no treatment were considered as comparators. METHODS OF STUDY SELECTION: We double-screened 9,131 abstracts and identified 136 studies that met our criteria. Studies were assessed for quality and strength of evidence by the systematic review group. TABULATION, INTEGRATION, AND RESULTS: Information regarding the participants, details on the intervention and comparator and outcomes were extracted from the eligible studies. Alternative therapies were similar or superior to estrogen or placebo with minimal increase in adverse events. Dose response was noted with vaginal DHEA and testosterone. Vaginal DHEA, ospemifene, erbium and fractional carbon dioxide (CO2) laser, polycarbophil-based vaginal moisturizer, tibolone, hyaluronic acid, and testosterone all improved subjective and objective signs of atrophy. Vaginal DHEA, ospemifene, tibolone, fractional CO2 laser, polycarbophil-based vaginal moisturizer, and testosterone improved sexual function. CONCLUSION: Most nonestrogen therapies are effective treatments for the various symptoms of GSM. There are insufficient data to compare nonestrogen options to each other.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause

Evans

Hobson

Aschkenazi

et al. 2023

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

“…To our knowledge, the effects of tibolone and transdermal estrogen on menopausal symptoms in surgically menopaused women have only been compared in one study [12]. The results showed that, in these women, tibolone was more effective at improving health-related quality of life, possibly because its androgenic effect lowers sex hormone-binding globulin levels, and results in improvements in pituitary β-endorphins-induced sexual problems or mood.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the Efficacy of Tibolone and Transdermal Estrogen in Treating Menopausal Symptoms in Postmenopausal Women

et al. 2019

View full text Add to dashboard Cite

Objectives: This study aimed to compare the efficacy of tibolone and transdermal estrogen in treating menopausal symptoms in postmenopausal women with an intact uterus. Methods: Overall, 26 women consumed tibolone orally and 31 women received transdermal estrogen gel mixed with progestogen. The menopause rating scale (MRS) was used to assess their menopausal symptoms at their first outpatient visit and 6 months later. Results: The transdermal estrogen group showed significant improvements in more items of the MRS questionnaire. There was a favorable change in body weight in the transdermal estrogen group compared with that in the tibolone group. Depressive mood, irritability, physical and mental exhaustion, sexual and bladder problems, and joint and muscular discomfort improved only in the transdermal estrogen group, whereas heart discomfort and vaginal dryness improved only in the tibolone group. Nevertheless, the intergroup differences in each item were insignificant after adjusting for body mass index and hypertension, which differed before treatment. Conclusions: Both the therapeutic options improved menopausal symptoms within 6 months of use. However, transdermal estrogen appeared to be more effective in preventing weight gain in menopausal women than tibolone.

show abstract

“…Depression scores were significantly reduced in the group allocated to CEE compared with placebo after 6 weeks. The study concluded oestrogen augmented the effect of antidepressants for the treatment of depression in peri‐menopausal and postmenopausal women 104 . Nagata et al 105 randomly allocated surgically menopaused women with hot flushes and depressive symptoms to one of two treatment arms for 8 weeks: CEE‐alone versus CEE + Fluvoxamine (a selective serotonin reuptake inhibitor [SSRI]) ( n = 42).…”

Section: Mood and Hrtmentioning

confidence: 99%

The effect of hormone replacement therapy on cognition and mood

Sharma

Davies

Kapoor

et al. 2022

Clinical Endocrinology

View full text Add to dashboard Cite

Objectives To summarise the available data regarding the effect of hormone replacement therapy (HRT) on cognition and mood in women. Background Complaints of impaired cognition and mood are common in the peri‐menopausal and menopausal period. There is debate as to whether HRT can ameliorate this phenomenon. Design A literature search of studies using electronic databases was conducted. Both randomised control trials and observational studies were included. Patients Perimenopausal and menopausal women. Results Due to the heterogenicity of results it is challenging to draw firm conclusions. The preparations used in many of the studies are older regimes no longer routinely used clinically. The notion of a ‘critical window’ for HRT is compelling, suggesting HRT has a positive impact on cognition when administered in the peri‐menopausal or early postmenopausal period but may have negative effects on cognition in the older, postmenopausal woman. The evidence would seem to suggest importance of hormonal replacement in woman undergoing a surgical menopause, especially when young. It remains unclear for how long they ought to continue HRT though until at least the natural age of the menopause seems reasonable. Evidence for a positive effect of HRT on mood is more convincing, though possibly more efficacious in the younger age group. The effect of HRT on anxiety is less clear. Conclusions Further study, particularly focusing on the more contemporaneous HRT preparations, is warranted before evidence‐based conclusions can be drawn.

show abstract

Effects of transdermal estradiol gel and oral tibolone on health‐related quality of life after surgical menopause

Abstract: Oral tibolone treatment was more effective than transdermal estradiol gel at improving HRQOL in Indian women with surgical menopause.

Cited by 9 publications

References 15 publications

Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause

Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause

Comparison of the Efficacy of Tibolone and Transdermal Estrogen in Treating Menopausal Symptoms in Postmenopausal Women

The effect of hormone replacement therapy on cognition and mood

Contact Info

Product

Resources

About